Herceptin生物製藥和生物相似藥市場：按類型、應用、分銷管道、支付方、給藥途徑、治療階段、患者群體和地區分類

預計到 2026 年，Herceptin生物製藥和生物相似藥市場規模將達到 34.9 億美元，到 2033 年將達到 51.9 億美元。預計 2026 年至 2033 年的複合年成長率將達到 5.8%。

近年來，受HER2陽性乳癌發生率上升和標靶治療需求日益成長的推動，Herceptin生物製藥及其生物相似藥的市場顯著成長。Herceptin（曲妥珠單抗）是一種單株抗體，可特異性標靶HER2蛋白，該蛋白在約20-30%的乳癌中過度表現。

這種藥物徹底改變了HER2陽性乳癌的治療模式，顯著提高了患者的預後和存活率。Herceptin適應症的持續擴展，包括其在HER2陽性轉移性胃癌治療的應用，進一步推動了市場成長。此外，生物相似藥的研發以及Herceptin與其他治療方法聯合應用的日益普及，也為市場成長開闢了新的途徑。本報告對Herceptin生技藥品和生物相似藥市場進行了詳細分析，揭示了其關鍵市場促進因素、限制、機會和未來前景。

市場動態

Herceptin生技藥品和生物相似藥市場受多種因素驅動，包括HER2陽性乳癌發病率的上升、標靶治療意識的增強以及對個人化醫療日益成長的需求。用於檢測HER2表達的伴隨診斷測試的開發也促進了市場成長，有助於識別最有可能從Herceptin治療中獲益的患者。然而，Herceptin治療的高成本正在抑制市場成長，並可能限制某些地區患者獲得治療的機會。此外，生物相似藥的出現以及Herceptin在部分國家的專利到期到期可能會影響原廠藥的市場佔有率。儘管存在這些挑戰，但市場仍存在巨大的成長機遇，包括Herceptin適應症擴展至其他HER2陽性癌症、新型聯合治療的開發以及新興市場對Herceptin的接受度提高。此外，旨在提高Herceptin療效和安全性的持續研發工作預計將在未來幾年推動市場成長。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數對Herceptin生物製藥和生物相似藥市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務績效和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份「Herceptin生物製劑和生物相似藥市場」報告針對產業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員將能夠透過分析Herceptin生物製藥和生物相似藥市場中使用的各種策略矩陣，更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章Herceptin生物製藥和生物相似藥市場：按類型分類，2021-2033年

• 生物製劑
• 生物相似藥

第5章Herceptin生物製藥與生物相似藥市場：依應用領域分類，2021-2033年

• 乳癌治療
• 胃癌治療

第6章Herceptin生物製藥與生物相似藥市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第7章Herceptin生物製藥與生物相似藥市場：依支付方分類，2021-2033年

• 民眾
• 私人的

第8章Herceptin生物製藥與生物相似藥市場：依給藥途徑分類，2021-2033年

• 靜脈
• 皮下

第9章Herceptin生物製藥與生物相似藥市場：依治療領域分類，2021-2033年

• 主要治療
• 二級治療
• 三線治療

第10章：Herceptin生物製藥與生物相似藥市場：依病患屬性分類，2021-2033年

• 年齡層

第11章Herceptin生物製藥與生物相似藥市場：按地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第12章 競爭格局

• Genentech（Roche）
• Amgen
• Pfizer
• Merck & Co.
• AbbVie
• Celgene
• Bristol-Myers Squibb
• AstraZeneca
• GSK（GlaxoSmithKline）
• Novartis
• Sanofi
• Teva Pharmaceuticals
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical Company
• EMD Serono

第13章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第14章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Herceptin Biologic and Biosimilar Market is estimated to be valued at USD 3.49 Bn in 2026 and is expected to reach USD 5.19 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.

Herceptin Biologic and Biosimilar Market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.

The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the Herceptin Biologic and Biosimilar Market, highlighting its key drivers, restraints, opportunities, and future prospects.

Market Dynamics

The Herceptin Biologic and Biosimilar Market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Herceptin Biologic and Biosimilar Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Herceptin Biologic and Biosimilar Marketreport caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Herceptin Biologic and Biosimilar Market

Market Segmentation

• Type Insights (Revenue, USD Bn, 2021 - 2033)
• Biologic
• Biosimilars
• Application Insights (Revenue, USD Bn, 2021 - 2033)
• Breast Cancer Treatment
• Gastric Cancer Treatment
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Payer Type Insights (Revenue, USD Bn, 2021 - 2033)
• Public
• Private
• Administration Route Insights (Revenue, USD Bn, 2021 - 2033)
• Intravenous
• Subcutaneous
• Treatment Line Insights (Revenue, USD Bn, 2021 - 2033)
• First-line Treatment
• Second-line Treatment
• Third-line Treatment
• Patient Demographics Insights (Revenue, USD Bn, 2021 - 2033)
• Age Groups
• Pediatric
• Adult
• Geriatric
• Gender
• Male
• Female

Regional Insights (Revenue, USD Bn, 2021 - 2033)

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Genentech (Roche)
• Amgen
• Pfizer
• Merck & Co.
• AbbVie
• Celgene
• Bristol-Myers Squibb
• AstraZeneca
• GSK (GlaxoSmithKline)
• Novartis
• Sanofi
• Teva Pharmaceuticals
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical Company
• EMD Serono

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Herceptin Biologic and Biosimilar Market, By Type
  • Herceptin Biologic and Biosimilar Market, By Application
  • Herceptin Biologic and Biosimilar Market, By Distribution Channel
  • Herceptin Biologic and Biosimilar Market, By Payer Type
  • Herceptin Biologic and Biosimilar Market, By Administration Route
  • Herceptin Biologic and Biosimilar Market, By Treatment Line
  • Herceptin Biologic and Biosimilar Market, By Patient Demographics
  • Herceptin Biologic and Biosimilar Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Herceptin Biologic and Biosimilar Market, By Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Biologic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Biosimilars
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Herceptin Biologic and Biosimilar Market, By Application, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Breast Cancer Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Gastric Cancer Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Herceptin Biologic and Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Herceptin Biologic and Biosimilar Market, By Payer Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Herceptin Biologic and Biosimilar Market, By Administration Route, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Herceptin Biologic and Biosimilar Market, By Treatment Line, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• First-line Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Second-line Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Third-line Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Herceptin Biologic and Biosimilar Market, By Patient Demographics, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Age Groups
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Pediatric
    • Adult
    • Geriatric
  • Gender
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Male
    • Female

11. Herceptin Biologic and Biosimilar Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

12. Competitive Landscape

• Genentech (Roche)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celgene
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK (GlaxoSmithKline)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• EMD Serono
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

14. References and Research Methodology

• References
• Research Methodology
• About us